167. マルファン症候群 Marfan syndrome Clinical trials / Disease details
臨床試験数 : 21 / 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2008-001462-81-IT (EUCTR) | 27/10/2008 | 17/03/2008 | Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND | Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND | Marfan Syndrome MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Trade Name: LORTAAN*28CPR RIV DIV 50MG INN or Proposed INN: Losartan Trade Name: LOBIVON*28CPR 5MG INN or Proposed INN: Nebivolol | OSPEDALE POLICLINICO S. MATTEO | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Italy |